Company Filing History:
4 out of 78 
1 out of 2 Years Active: 2016-2021
Title: Elisabetta Ciani: Innovator in CDKL5 Research
Introduction
Elisabetta Ciani is a prominent inventor based in Bologna, Italy. She has made significant contributions to the field of biomedical research, particularly in the study of CDKL5 disorders. With a total of five patents to her name, her work has the potential to impact the treatment of various neurological conditions.
Latest Patents
Ciani's latest patents include innovative developments such as TATk-CDKL5 fusion proteins, compositions, formulations, and their uses. These patents disclose compositions and formulations containing a TATk-CDKL5 fusion protein, along with methods for producing this protein from vectors containing a TATk-CDKL5 cDNA. Additionally, she has developed methods for transducing cells with these vectors and the TATk-CDKL5 fusion protein. Another significant patent involves the treatment of CDKL5 disorders using the GSK3β inhibitor tideglusib, providing methods for treating CDKL5 deficiency with tideglusib or its derivatives.
Career Highlights
Throughout her career, Elisabetta Ciani has worked with esteemed institutions such as Alma Mater Studiorum - Università di Bologna and Università di Bologna. Her research has focused on advancing the understanding and treatment of CDKL5-related disorders, showcasing her dedication to improving patient outcomes.
Collaborations
Ciani has collaborated with notable colleagues in her field, including Franco Laccone and Claudia Fuchs. These partnerships have further enriched her research and contributed to the development of her innovative patents.
Conclusion
Elisabetta Ciani's work exemplifies the intersection of innovation and medical research. Her contributions to the understanding and treatment of CDKL5 disorders highlight her role as a leading inventor in the field. Through her patents and collaborations, she continues to pave the way for advancements in biomedical science.